Tightening our understanding of intensive glycaemic control

Affiliations

¹ Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. Electronic address: will.herrington@ndph.ox.ac.uk.
² Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.

Comment

William G Herrington et al. Lancet Diabetes Endocrinol. 2017 Jun.

. 2017 Jun;5(6):405-407.

doi: 10.1016/S2213-8587(17)30095-5. Epub 2017 Mar 30.

¹ Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. Electronic address: will.herrington@ndph.ox.ac.uk.
² Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.

No abstract available

Comment on

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group. Zoungas S, et al. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30. Lancet Diabetes Endocrinol. 2017. PMID: 28365411